UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients

Cancer Immunology, Immunotherapy, 2021-07, Vol.70 (7), p.2095-2102

2021

Volltextzugriff (PDF)

Kv1.3 Channels Are a Therapeutic Target for T Cell-Mediated Autoimmune Diseases

Proceedings of the National Academy of Sciences - PNAS, 2006-11, Vol.103 (46), p.17414-17419

2006

Volltextzugriff (PDF)

758 Biomarkers associated with blockade of prostaglandin E2 signaling by TPST-1495: a novel, dual-antagonist of E-prostanoid receptors 2 and 4

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A854-A854

2023

Volltextzugriff (PDF)

ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors

Proceedings of the National Academy of Sciences - PNAS, 2011-05, Vol.108 (19), p.7938-7943

2011

Volltextzugriff (PDF)

Assessment of Seasonal Influenza A Virus-Specific CD4 T-Cell Responses to 2009 Pandemic H1N1 Swine-Origin Influenza A Virus

Journal of Virology, 2010-04, Vol.84 (7), p.3312-3319

2010

Volltextzugriff (PDF)

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e007340

2024

Volltextzugriff (PDF)

Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries

PloS one, 2012-01, Vol.7 (1), p.e29949-e29949

2012

Volltextzugriff (PDF)

Recognition of HLA Class I–Restricted β-Cell Epitopes in Type 1 Diabetes

Diabetes (New York, N.Y.), 2006-11, Vol.55 (11), p.3068-3074

2006

Volltextzugriff (PDF)

Recruiting the Immune System Against Disease: Lessons for Clinical and Systems Pharmacology

CPT: pharmacometrics and systems pharmacology, 2019-07, Vol.8 (7), p.436-439

2019

Volltextzugriff (PDF)

Identification of Novel HLA-A0201–Restricted Epitopes in Recent-Onset Type 1 Diabetic Subjects and Antibody-Positive Relatives

Diabetes (New York, N.Y.), 2006-11, Vol.55 (11), p.3061-3067

2006

Volltextzugriff (PDF)

1338 Crystallography-guided characterization of novel cytosolic DNase 3’ repair exonuclease 1 (TREX1) inhibitors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1492-A1492

2023

Volltextzugriff (PDF)

275 Translational endpoints associated with STK11 mutations in patients with non-squamous NSCLC

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A300-A300

2020

Volltextzugriff (PDF)

Pharmacodynamics and gene expression analysis of patients with renal cell carcinoma treated with combination nivolumab and TPST-1120 in a phase I clinical trial (NCT03829436)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.438-438

2024

Volltextzugriff (PDF)

Changes in autoreactive T cell avidity during type 1 diabetes development

Clinical immunology (Orlando, Fla.), 2009-09, Vol.132 (3), p.312-320

2009

Volltextzugriff (PDF)

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Journal of clinical oncology, 2021-09, Vol.39 (27), p.2991-3001

2021

Volltextzugriff (PDF)

Maintenance of immune tolerance to a neo-self acetylcholine receptor antigen with aging: implications for late-onset autoimmunity

The Journal of immunology (1950), 2010-06, Vol.184 (11), p.6067-6075

2010

Volltextzugriff (PDF)

Discrete T Cell Populations with Specificity for a Neo-Self-Antigen Bear Distinct Imprints of Tolerance

Journal of Immunology, 2007-03, Vol.178 (6), p.3544-3550

2007

Volltextzugriff (PDF)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Clinical cancer research, 2023-02, Vol.29 (4), p.754-763

2023

Volltextzugriff (PDF)

Abstract 2130: Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2130-2130

2023

Volltextzugriff (PDF)

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Clinical cancer research, 2020-12, Vol.26 (23), p.6196-6203

2020

Volltextzugriff (PDF)

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

Clinical cancer research, 2022-06, Vol.28 (12), p.2567-2578

2022

Volltextzugriff (PDF)

Modeling of Proliferating CD4 and CD8 T‐Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma

Clinical pharmacology and therapeutics, 2023-10, Vol.114 (4), p.874-882

2023

Volltextzugriff (PDF)

A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3107-3107

2023

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(63)
Dissertationen
(1)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(28)
Humans
(22)
Immunology
(14)
Animals
(9)
Oncology
(9)
Immunotherapy
(8)
Adult
(7)
Allergy And Immunology
(7)
Antigens
(7)
Female
(7)
Mice
(7)
Amino Acid Sequence
(6)
Biological And Medical Sciences
(6)
Cd4-Positive T-Lymphocytes - Immunology
(6)
Diabetes Mellitus, Type 1 - Immunology
(6)
Diabetes
(5)
Diabetes. Impaired Glucose Tolerance
(5)
Endocrine Pancreas. Apud Cells
(5)
Endocrinopathies
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients

Kv1.3 Channels Are a Therapeutic Target for T Cell-Mediated Autoimmune Diseases

758 Biomarkers associated with blockade of prostaglandin E2 signaling by TPST-1495: a novel, dual-antagonist of E-prostanoid receptors 2 and 4

ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors

Assessment of Seasonal Influenza A Virus-Specific CD4 T-Cell Responses to 2009 Pandemic H1N1 Swine-Origin Influenza A Virus

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors

Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries

Recognition of HLA Class I–Restricted β-Cell Epitopes in Type 1 Diabetes

Recruiting the Immune System Against Disease: Lessons for Clinical and Systems Pharmacology

Identification of Novel HLA-A0201–Restricted Epitopes in Recent-Onset Type 1 Diabetic Subjects and Antibody-Positive Relatives

1338 Crystallography-guided characterization of novel cytosolic DNase 3’ repair exonuclease 1 (TREX1) inhibitors

275 Translational endpoints associated with STK11 mutations in patients with non-squamous NSCLC

Pharmacodynamics and gene expression analysis of patients with renal cell carcinoma treated with combination nivolumab and TPST-1120 in a phase I clinical trial (NCT03829436)

Changes in autoreactive T cell avidity during type 1 diabetes development

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Maintenance of immune tolerance to a neo-self acetylcholine receptor antigen with aging: implications for late-onset autoimmunity

Discrete T Cell Populations with Specificity for a Neo-Self-Antigen Bear Distinct Imprints of Tolerance

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Abstract 2130: Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

Modeling of Proliferating CD4 and CD8 T‐Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma

A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors

Suchergebnisse filtern